Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezpegaldesleukin SAD in healthy Japanese and Caucasian subjects
NCT04133116Phase 1Completed
- Sponsor
- Nektar Therapeutics
- Start
- Oct 2019
- Primary completion
- Mar 2020
- Modality
- Biologic, rProtein (Recombinant Protein), Polyethylene glycol conjugate
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE), atopic dermatitis (AD) and psoriasis comparing Rezpegaldesleukin with Placebo (2 arms). Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration. Started Oct 2019; status: completed.
02
Drugs
rezpegaldesleukin
03
Conditions
systemic lupus erythematosus (SLE)atopic dermatitis (AD)psoriasis
Beyond the preview
Go deeper on NCT04133116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04133116.